Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genasense Phase III Trial In Multiple Myeloma Fails

This article was originally published in The Pink Sheet Daily

Executive Summary

Genta says it will analyze the trial data “in considerably more detail before making decisions regarding the Genasense program in myeloma.” News of the failed trial comes on the heels of a separate Phase III study of oblimersen in chronic lymphocytic leukemia that met its primary endpoint but failed to show a survival benefit.
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS058237

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel